Skip to content

Research Analysts Set Expectations for ALX Oncology Holdings Inc.'s FY2022 Earnings (NASDAQ:ALXO) – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Rating) – Analysts at Cantor Fitzgerald decreased their FY2022 earnings per share estimates for ALX Oncology in a research report issued on Tuesday, August 9th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($3.23) per share for the year, down from their prior forecast of ($2.69). The consensus estimate for ALX Oncology’s current full-year earnings is ($2.73) per share. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2023 earnings at ($3.93) EPS.
ALX Oncology (NASDAQ:ALXOGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.17.
Other analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of ALX Oncology in a research note on Monday, May 16th. Stifel Nicolaus dropped their price objective on ALX Oncology from $35.00 to $16.00 in a report on Monday, June 6th. Piper Sandler dropped their price objective on ALX Oncology from $70.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, May 18th. Finally, Credit Suisse Group lowered their price target on ALX Oncology from $43.00 to $38.00 and set an “outperform” rating on the stock in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $39.83.

ALX Oncology Price Performance

ALX Oncology stock opened at $12.79 on Thursday. ALX Oncology has a 1-year low of $5.82 and a 1-year high of $81.19. The stock has a market cap of $521.19 million, a PE ratio of -4.70 and a beta of 2.21. The stock’s fifty day moving average is $9.17 and its two-hundred day moving average is $12.79.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its position in ALX Oncology by 8.5% during the 1st quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after purchasing an additional 1,500 shares during the period. DekaBank Deutsche Girozentrale boosted its position in ALX Oncology by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 24,300 shares of the company’s stock worth $421,000 after purchasing an additional 2,200 shares during the period. Amalgamated Bank purchased a new stake in ALX Oncology during the 1st quarter worth $49,000. Nisa Investment Advisors LLC purchased a new stake in ALX Oncology during the 4th quarter worth $48,000. Finally, Virtus ETF Advisers LLC boosted its position in ALX Oncology by 94.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 6,844 shares of the company’s stock worth $147,000 after purchasing an additional 3,318 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

(Get Rating)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

See Also

Earnings History and Estimates for ALX Oncology (NASDAQ:ALXO)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ALX Oncology, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ALX Oncology wasn’t on the list.
While ALX Oncology currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source

Share:

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

More Posts